Menu

Updates in COVID-19 Therapies: What You Need to Know to Optimize Care of Hospitalized Patients in 2022

When:
October 14, 2022 @ 11:00 am – 12:00 pm
2022-10-14T11:00:00+00:00
2022-10-14T12:00:00+00:00

Updates in COVID-19 Therapies: What You Need to Know to Optimize Care of Hospitalized Patients in 2022

REGISTER FOR LIVE VIRTUAL PROGRAM

A Virtual Meeting Preceding IDWeek™ 2022

 

Friday, October 14, 2022

11:00 AM – 12:00 PM ET Virtual Symposium

Please note this virtual program is 11:00AM Eastern, 10:00AM, Central, 9:00AM Mountain and 8:00AM Pacific.

PROGRAM FEATURES

  • Online personalized quality-improvement poster-generation portal
  • Downloadable case study video

FACULTY

William A. Fischer II, MD
Associate Professor of Medicine, Pulmonary and Critical Care Medicine
Director of Emerging Pathogens
Institute for Global Health and Infectious Diseases
The University of North Carolina
Chapel Hill, NC

LEARNING OBJECTIVES

  • Evaluate the burden of COVID-19 in the United States and the need to use therapies to reduce mortality risk in hospitalized patients
  • Integrate the latest treatment guidelines and appropriate strategies into the management of hospitalized patients with SARS-CoV-2 infection
  • Analyze the results of the latest clinical trials concerning the use of novel therapies to reduce the risk of mortality in patents hospitalized as a result of COVID-19

TARGET AUDIENCE

This activity is designed to meet the educational needs of intensive care physicians, pulmonologists, rheumatologists, infectious disease specialists, emergency physicians, hospitalists, pharmacists, nurses, nurse practitioners, physician’s assistants, and other members of the multidisciplinary team to ensure optimal patient outcomes in inpatient management of COVID-19 infection.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with COVID-19.

CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hours of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the live event at [email protected]

 

 

REGISTER FOR LIVE VIRTUAL PROGRAM

 

Scroll to Top
Menu

Updates in the Treatment and Prevention of COVID-19​

Molnupiravir, an Oral Antiviral, Reduced the Risk of Hospitalization or Death in Patients with Mild-to-Moderate COVID-19

Molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death by 50% in an interim analysis of the phase 3 MOVe-OUT trial. The planned analysis evaluated data from 775 at-risk, non-hospitalized adult patients with mild-to-moderate COVID-19. All patients enrolled had at least one risk factor associated with poor COVID-19 outcomes and were randomized within 5 days of symptom onset. At day 29, 7.3% of patients who received molnupiravir were either hospitalized or died, compared with 14.1% of placebo-treated patients (P= .0012). No deaths were reported in patients receiving molnupiravir, compared with 8 deaths in patients who received placebo. The incidence of any adverse event was comparable in the molnupiravir and placebo groups (35% and 40%, respectively). Discontinuation due to adverse events was lower with molnupiravir (1.3%) versus placebo (3.4%).

Reference:

https://www.contagionlive.com/view/molnupiravir-could-become-first-authorized-covid-19-pill